Gerben J C Zwezerijnen
Overview
Explore the profile of Gerben J C Zwezerijnen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boellaard R, Zwezerijnen G, Buvat I, Champion L, Hovhannisyan-Baghdasarian N, Orlhac F, et al.
J Nucl Med
. 2025 Mar;
PMID: 40081961
Measuring total metabolic tumor volume (TMTV) on F-FDG PET/CT images in clinical practice requires a fast, reliable, and easy-to-perform multilesional segmentation workflow. We conducted a field test to derive total...
2.
van der Heijden W, van Velden F, Hemke R, Doorschodt T, Boellaard R, van der Laken C, et al.
EJNMMI Phys
. 2025 Mar;
12(1):20.
PMID: 40059265
Purpose: Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease which involves the axial skeleton. Quantitative sodium fluoride-18 (Na[F]F) PET/CT is a new imaging approach promising for accurate diagnosis and treatment...
3.
Knip J, Iqbal R, Bonjer E, Mammatas L, van Zweeden A, Perin P, et al.
Radiology
. 2025 Mar;
314(3):e241850.
PMID: 40035673
Background According to current guidelines, staging of patients with locally advanced breast cancer and local-regional recurrent breast cancer is preferably performed with PET using 2-fluorine 18-fluoro-2-deoxy-d-glucose (F-FDG). However, F-FDG PET...
4.
Sobejana M, Al Beiramani M, Zwezerijnen G, van der Kooi A, Raaphorst J, Meskers C, et al.
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002878
This retrospective study explored the qualitative and quantitative assessment of F18-fluordeoxyglucose ([F]-FDG) positron emission tomography and computed tomography (PET/CT) scans to assess pathophysiological muscle glucose uptake in patients with a...
5.
Jansen R, Kemp P, Wiegers S, de Graaf P, van Schie A, Martens R, et al.
Otol Neurotol
. 2025 Jan;
46(3):295-302.
PMID: 39794893
Objective: This study aims to identify 18 F-FDG-PET imaging features for improving treatment response evaluation in patients with necrotizing otitis externa (NOE), aiding in the difficult differentiation between sterile inflammation...
6.
Broens B, Nossent E, Meijboom L, Zwezerijnen G, Spierings J, de Vries-Bouwstra J, et al.
Arthritis Res Ther
. 2024 Dec;
26(1):219.
PMID: 39702262
Background: This study aimed to assess the quantitative uptake of F-FDG PET-CT in the lungs of patients with early severe diffuse cutaneous systemic sclerosis (SSc) with and without interstitial lung...
7.
Baraliakos X, de Jongh J, Poddubnyy D, Zwezerijnen G, Hemke R, Glatt S, et al.
Ther Adv Musculoskelet Dis
. 2024 Dec;
16:1759720X241293944.
PMID: 39620046
Background: The efficacy and safety of bimekizumab (BKZ), an inhibitor of interleukin (IL)-17F in addition to IL-17A, has been established in axial spondyloarthritis (axSpA). Early assessment of new bone formation...
8.
Smith C, Zwezerijnen G, Wiegers S, Jauw Y, Lugtenburg P, Zijlstra J, et al.
Diagnostics (Basel)
. 2024 Nov;
14(22).
PMID: 39594197
Background: Bleomycin is an oncolytic and antibiotic agent used to treat various human cancers because of its antitumor activity. Unfortunately, up to 46% of the patients treated with bleomycin develop...
9.
Ferrandez M, Golla S, Eertink J, Wiegers S, Zwezerijnen G, Heymans M, et al.
J Nucl Med
. 2024 Oct;
65(11):1802-1807.
PMID: 39362767
The aim of this study was to validate a previously developed deep learning model in 5 independent clinical trials. The predictive performance of this model was compared with the international...
10.
Eisses B, van Geel J, Brouwers A, Bensch F, Elias S, Kuip E, et al.
J Nucl Med
. 2024 Sep;
65(10):1540-1547.
PMID: 39237347
Understanding which patients with human epidermal growth factor receptor 2 (HER2)-negative or -low metastatic breast cancer (MBC) benefit from HER2-targeted strategies is urgently needed. We assessed the whole-body heterogeneity of...